ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Visceral Leishmaniasis in Latin America and therapy perspectives

Journal: REVISTA MVZ CÓRDOBA (Vol.22, No. 4)

Publication Date:

Authors : ;

Page : 6075-6088

Keywords : Disease; drug therapy; Leishmania infantum; Lutzomyia; vector;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

In Latin America, visceral leishmaniasis is caused by Leishmania infantum. In this geographical area, main vectors associated with transmission are Lutzomyia longipalpis and Lutzomyia evansi, with dogs being incriminated as the main reservoir involved in transmission of the disease. This pathology primarily affects children between 0 - 5 years, a highly susceptible population where socio-economic, environmental and nutritional factors affects the pathological outcome and increase the likelihood of vector-human contact. According to the World Health Organization (WHO) recommended treatment for Visceral Leishmaniasis is liposomal amphotericin B, a drug with a limited and variable availability between countries depending on market prices, which leaves pentavalent antimonial as the most widely used treatment despite the associated toxic effects. In the Americas, evidence on the efficacy of single-dose (monotherapy) and combination therapies as options for treating these parasites is required.

Last modified: 2017-11-23 23:24:16